BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MT-304 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MT-304\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07334119-2628@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:MT-304: Phase 1 readout est. (NCT07334119)
DESCRIPTION:MT-304\, phase 1.\nStudy: Safety\, Pharmacokinetics\, Pharmacod
 ynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Ex
 pressing Solid Tumors\nEstimated primary completion: 31 January 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mt-304#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07334119
URL:https://assetmemo.bio/drug/mt-304#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
